chevron_leftBack
As of 24 April 2025, Perseus Proteomics Inc. has a market cap of $38.79M USD, ranking #26235 globally and #2946 in Japan. It ranks #2652 in the Healthcare sector, and #76 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$38.79MUSD
5.53B JPY
Enterprise Value
$25.5MUSD
3.65B JPY
Revenue (TTM)
$781.69KUSD
111.39M JPY
EBITDA (TTM)
-$5.85MUSD
-837.39M JPY
Net Income (TTM)
-$6.31MUSD
-898.75M JPY
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Takuya Yokokawa
open_in_new
Employees
25
Founded
2001
Website
ppmx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 4.3% | 3.4% | -62% | -30% | -35% | 18% |
Upcoming Earnings
Earnings Date
Thu, May 15
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4882
株式会社 ペルセウスプロテオミクス
ISIN: JP3836800007
Shares Out.:
Shares Outstanding:
14.749M1
Shares Float:
12.763M2
|
391 JPY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Perseus Proteomics Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
